P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

[1]  Issa J Dahabreh,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. , 2008, Clinical therapeutics.

[2]  K. Pavelka,et al.  The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. , 2007, Arthritis and rheumatism.

[3]  J. F. Schindler,et al.  p38 Pathway Kinases as Anti-inflammatory Drug Targets , 2007, Journal of dental research.

[4]  R. Ji,et al.  p38 MAPK, microglial signaling, and neuropathic pain , 2007, Molecular pain.

[5]  J. Ashwell.  The many paths to p38 mitogen-activated protein kinase activation in the immune system , 2006, Nature Reviews Immunology.

[6]  S. Abramson,et al.  Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. , 2006, Advanced drug delivery reviews.

[7]  S. Ho,et al.  Inhibition of p38 mitogen‐activated protein kinase attenuates interleukin‐1β‐induced thermal hyperalgesia and inducible nitric oxide synthase expression in the spinal cord , 2005, Journal of neurochemistry.

[8]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[9]  K. Aoki,et al.  R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. , 2005, European journal of pharmacology.

[10]  F. Berenbaum.  Signaling transduction: target in osteoarthritis , 2004, Current opinion in rheumatology.

[11]  J. Saklatvala.  The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. , 2004, Current opinion in pharmacology.

[12]  S. Genevay,et al.  Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study , 2004, Annals of the rheumatic diseases.

[13]  W. B. van den Berg,et al.  Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. , 2003, Osteoarthritis and cartilage.

[14]  J. Pelletier,et al.  In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. , 2003, Arthritis and rheumatism.

[15]  C. Woolf,et al.  p38 Mitogen-Activated Protein Kinase Is Activated after a Spinal Nerve Ligation in Spinal Cord Microglia and Dorsal Root Ganglion Neurons and Contributes to the Generation of Neuropathic Pain , 2003, The Journal of Neuroscience.

[16]  L. Sorkin,et al.  Tumor Necrosis Factor-α Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons , 2003, The Journal of Neuroscience.

[17]  S. Hanauer.  Maintenance infliximab for Crohn's disease , 2002, The Lancet.

[18]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[19]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[20]  A. Freemont,et al.  Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. , 2001, Osteoarthritis and cartilage.

[21]  M. Dougados,et al.  Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. , 2001, Arthritis and rheumatism.

[22]  M. Tortorella,et al.  The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. , 2001, Osteoarthritis and cartilage.

[23]  S. Patel,et al.  p38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia. , 2001, European journal of pharmacology.

[24]  C. Sommer,et al.  Etanercept reduces hyperalgesia in experimental painful neuropathy , 2001, Journal of the peripheral nervous system : JPNS.

[25]  S. Abramson,et al.  Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. , 2001, Arthritis and rheumatism.

[26]  Adam Sapirstein,et al.  Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity , 2001, Nature.

[27]  M. Goldring,et al.  Osteoarthritis and cartilage: The role of cytokines , 2000, Current rheumatology reports.

[28]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[29]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[30]  M. Yaron,et al.  Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. , 2000, Arthritis and rheumatism.

[31]  J. Pelletier,et al.  Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. , 2000, Osteoarthritis and cartilage.

[32]  J. Siekierka,et al.  RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. , 1999, The Journal of pharmacology and experimental therapeutics.

[33]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[34]  J. Pelletier,et al.  In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. , 1998, The Journal of rheumatology.

[35]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[36]  J C Lee,et al.  Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. , 1997, Biochemical and biophysical research communications.

[37]  D E Griswold,et al.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.

[38]  R. Myers,et al.  Endoneurial injection of TNF-α produces neuropathic pain behaviors , 1996 .

[39]  M. Lotz,et al.  Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. , 1996, The Journal of clinical investigation.

[40]  J. Pelletier,et al.  Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. , 1996, Arthritis and rheumatism.

[41]  B. Wilbrink,et al.  Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. , 1990, Arthritis and rheumatism.

[42]  R. Dubner,et al.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.

[43]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[44]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[45]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[46]  J. Boehm,et al.  Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. , 2000, Arthritis and rheumatism.

[47]  R. Myers,et al.  Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. , 1996, Neuroreport.

[48]  G. Katona.  Osteoarthritis--an inflammatory disease? , 1984, International journal of tissue reactions.